Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $1.2 million.

  • Lineage Cell Therapeutics' Share-based Compensation fell 9.85% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 3.05%. This contributed to the annual value of $5.1 million for FY2024, which is 9.42% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Share-based Compensation stood at $1.2 million for Q3 2025, which was down 3.15% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Share-based Compensation ranged from a high of $1.3 million in Q3 2024 and a low of $539,000 during Q1 2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Share-based Compensation value was $1.2 million (recorded in 2025), while the average stood at $1.2 million.
  • Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Share-based Compensation showed a top increase of 128.34% in 2021 and a maximum decrease of 13.90% in 2021.
  • Lineage Cell Therapeutics' Share-based Compensation (Quarterly) stood at $918,000 in 2021, then increased by 4.47% to $959,000 in 2022, then increased by 10.53% to $1.1 million in 2023, then grew by 24.06% to $1.3 million in 2024, then declined by 9.85% to $1.2 million in 2025.
  • Its Share-based Compensation was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.